Clinical Trial Update: Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing baricitinib for treating adults with Pyoderma gangrenosum has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyoderma Gangrenosum

Drugs mentioned

• Baricitinib (Olumiant) (baricitinib)

Snippet

Sponsor: Oregon Health and Science University | Conditions: Pyoderma Gangrenosum, Skin Diseases | Phase 2 | Status: COMPLETED